NanoViricides, Inc. (NNVC) stock
Close on Nov 13, 2026Market cap $31.40MP/E –Yield –
NanoViricides, Inc. reported revenue of $0 for the twelve months to Jun 30, 2026. Free cash flow was -$7.78M. At the latest close the market valued the company at $31.40M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $31.40M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.62
- Dividend yield
- –
- Free cash flow yield
- -24.78%
Fundamentals
- Revenue
- $0
- Net income
- -$8.22M
- EPS, diluted
- -$0.41
- Free cash flow
- -$7.78M
- Book value per share
- $0.39
- Diluted shares
- 22M
Trading
- Previous close
- $1.35
- Open
- $1.35
- Day's range
- $1.21 – $1.35
- Volume
- 171,556
- Average volume (20 days)
- 169,361
- Beta (5 years)
- 0.77
- 52-week range
- $0.85 – $1.93
- RSI (14 days)
- 41.6
- Volatility (1 year)
- 90.0%
- Relative volume
- 0.46×
- WACC
- 9.0%
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | NNVC | S&P 500 | Difference | NNVC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -6.8% | -3.0% | −3.8 pts | ||
| 3 months | -9.6% | -2.8% | −6.8 pts | ||
| Year to date | +8.8% | +11.5% | −2.6 pts | ||
| 1 year | -8.9% | +13.5% | −22.4 pts | ||
| 3 years | +2.5% | +77.7% | −75.2 pts | +0.8% | +21.1% |
| 5 years | -73.7% | +72.6% | −146.3 pts | -23.4% | +11.5% |
| 10 years | -95.5% | +308.2% | −403.7 pts | -26.7% | +15.1% |
Fifteen years at a glance
Fiscal years 2012 to 2026, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases NanoViricides filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
About NanoViricides
Pharmaceutical Preparations
NanoViricides is a clinical-stage biopharmaceutical company that develops antiviral therapies using nanomedicine technology. The company designs host-mimetic, direct-acting nanomachines that dismantle target viruses by binding to conserved cellular attachment receptors. Its primary drug candidate, NV-387, is an oral formulation evaluated for treating viral diseases such as COVID-19, mpox, and Ebola. Other development programs include NV-HHV-1 for herpesviruses and NV-HIV-1 for human immunodeficiency virus. NanoViricides is currently in the development stage and has no commercial products, active customers, or operational revenue.
Company profile, executives and historyNanoViricides stock: common questions
What is NanoViricides's stock price?
NNVC closed at $1.23 on Nov 13, 2026, down 8.89% on the day. Over the past 52 weeks it traded between $0.85 and $1.93.
What is NanoViricides's market cap?
NanoViricides was worth $31.40M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is NNVC's P/E ratio?
NanoViricides lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.41), so it has no meaningful P/E ratio.
How much revenue does NanoViricides make?
NanoViricides reported revenue of $0 for the twelve months to Jun 30, 2026.
Does NanoViricides pay a dividend?
No. NanoViricides has not paid a cash dividend over the last twelve months.
How has NNVC stock performed over the past year?
Including dividends, NNVC returned -8.9% over the past year, against +13.5% for the S&P 500.
How many NNVC shares are sold short?
1M shares were sold short at the latest FINRA report, 3.18% of the float, or 4.2 days of average trading volume.
Who are NanoViricides's competitors?
Companies most similar to NanoViricides by business, industry and size include COCP, ASMB, DCOY, BIXT, ANTX.
See a number that looks wrong?